Correspondence on ACMG STATEMENT: ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG) by Miller et al
Kathryn A. McGurk, Sean L. Zheng, Albert Henry, Katherine Josephs, Matthew Edwards, Antonio de Marvao, Nicola Whiffin, Angharad Roberts, Thomas R. Lumbers, Declan P. O Regan, James S. Ware
Unverified — Be the first to reproduce this paper.
ReproduceAbstract
We were interested to read the recent update on recommendations for reporting of secondary findings in clinical sequencing1, and the accompanying updated list of genes in which secondary findings should be sought (ACMG SF v3.0)2. Though the authors discuss challenges around incomplete penetrance in considerable detail, we are concerned that the recommendations do not fully convey the degree of uncertainty regarding the penetrance of variants in genes associated with inherited cardiomyopathies, which make up almost a quarter of the list. Since penetrance is incomplete and age-related, individuals found to carry variants will often require surveillance, rather than a one-off definitive diagnostic assessment. There is a lack of evidence regarding benefits, harms, and healthcare costs associated with opportunistic screening.